Open AccessGliosarcoma: Report of Four Cases and Review of Literature
Author(s) -
M Benlemlih,
Marnouche EA,
M Hommadi,
A Maghous,
Bazine Bazine,
K Andaloussi,
M Elmarjany,
K Hadadi,
H Sifat
Publication year - 2022
Publication title -
scholars journal of medical case reports
Language(s) - English
Resource type - Journals
eISSN - 2347-9507
pISSN - 2347-6559
DOI - 10.36347/sjmcr.2022.v10i02.020
Subject(s) - gliosarcoma , gsm , medicine , malignancy , temozolomide , radiation therapy , glioblastoma , cancer research , computer science , telecommunications
Gliosarcoma (GSM) is a rare central nervous system malignancy; it represents less than 0.5% of all intracranial tumors. GSM usually affects often male in their fifth to sixth decade of life with supratentorial location especially in temporal lobes. The management of GS is extrapolated from glioblastoma with maximal gross total resection, and adjuvant radiotherapy with/without temozolomide. The prognosis is poor with median survival ranged from 06 to 14.8 months. The optimal treatment of GSM is unclear because of the lack of prospective studies. We report 04 cases (three cases of primary GSM and one case of secondary GSM) treated in our department of radiotherapy. Unfortunately, this publication confirmed the poor prognosis and the aggressive behavior of GSM tumors.